Thyroid Hormone Replacement for Subclinical Hypothyroidism and Chronic Heart Failure (ThyroHeart-CHF)

Phase 4

• Conditions: Subclinical Hypothyroidism; Heart Failure
• Interventions: Drug: Levothyroxine

• Registration Number: NCT03096613
• Lead Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital

Brief Summary

Based on accumulating evidence showing that hypothyroid status is associated with poor prognosis among heart failure (HF) patients, the study is designed to evaluate whether replacement treatment with levothyroxine could have beneficial effects on patients with HF and subclinical hypothyroidism. The study is a prospective, randomized, parallel-group trial to assess the efficacy and safety of levothyroxine replacement on evidence-based HF standard therapy in stable chronic heart failure patients with subclinical hypothyroidism.

Detailed Description

The primary objective of this trial is to determine whether the 24-week L-T4 replacement therapy, as an adjunct to standard treatment, would improve exercise capability in chronic systolic heart failure patients with subclinical hypothyroidism compared to the standard treatment.

Study Timeline

• Study First Submitted: 2017-03-25
• Study First Submitted QC: 2017-03-25
• Study First Posted: 2017-03-30
• Study Start: 2017-04-18
• Status Verified: 2018-03
• Last Update Submitted: 2018-03-28
• Last Update Posted: 2018-03-29
• Primary Completion: 2019-02
• Study Completion: 2019-02

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 124

Inclusion Criteria

• Aged 18 years or older, male or female.
• Systolic heart failure with New York Heart Association (NYHA) class II-III.
• Left ventricular ejection fraction (LVEF) less than 40% by echocardiography during screening and randomization.
• SCH (TSH: upper limits of normal (ULN) -10mIU/L, and FT4 level within reference range).
• Having received standard HF therapy for at least 2 weeks, having reached target dose or max tolerable dose.
• Provided informed consent.

Exclusion Criteria

• Acute heart failure or acute exacerbation of chronic heart failure within the past 2 weeks.
• Scheduled cardiac resynchronization therapy or heart transplantation.
• History of malignant tumor or life expectancy under 12 months.
• Already on medications that may affect thyroid function (L-T4, carbimazole, propylthiouracil, amiodarone, lithium).
• Pregnancy and lactation period.
• Participation in another clinical trial within the past 30 days.
• Contraindication or intolerance to evidence-based therapy for CHF, such as beta-blocker, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.
• Known hypersensitivity to the trial treatment(s) or diluents (when applicable), including placebo or other comparator drug(s).
• Untreated adrenal insufficiency.
• Untreated pituitary insufficiency.
• Untreated thyrotoxicosis.
• Treatment with levothyroxine must not be initiated in patients with acute myocardial infarction, acute myocarditis, or acute pancarditis.
• Severe renal dysfunction (eGFR≤30 ml/min/1.73m2).
• Significant hepatic impairment (Serum GPT > 120 U/L).
• Any disorder which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Levothyroxine group	Levothyroxine	The patients allocated to levothyroxine group receive levothyroxine with a starting dose of 12.5ug.

Primary Outcome Measures

Name	Time	Method
Distance difference of Six-minute Walk Test (6MWT) between week 24 and baseline	Within 6 months of patient enrolled

Secondary Outcome Measures

Name	Time	Method
Difference of the plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) level between week 24 and baseline	Within 6 months of patient enrolled
Change in NYHA classification between week 24 and baseline.	Within 6 months of patient enrolled
Composite of cardiovascular death or heart failure re-hospitalization during the 24 weeks treatment	Within 6 months of patient enrolled
Composite of cardiovascular death, re-hospitalization for cardiovascular disease, severe arrhythmia, and stroke during the 24 weeks treatment	Within 6 months of patient enrolled
Difference of echocardiographic and cardiac magnetic resonance imaging measures between week 24 and baseline	Within 6 months of patient enrolled
Difference of MLHFQ between week 24 and baseline	Within 6 months of patient enrolled
Difference of serum lipid profiles between week 24 and baseline	Within 6 months of patient enrolled
Adverse events	Within 6 months of patient enrolled

Trial Locations

Locations (1)

Chinese Academy of Medical Sciences, Fuwai Hospital; 🇨🇳 Beijing, Beijing, China